Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.47 |
| ▸ | TERT | O14746 | 3/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.47 |
| ▸ | PPARD | Q03181 | 3/20 | 0.47 |
| ▸ | PPARA | Q07869 | 3/20 | 0.47 |
| ▸ | TOP1 | P11387 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.47 |
| ▸ | GMNN | O75496 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL417768 | 1.00 | FAAH (0.47) | FAAHTERTPTPN1PPARGPPARD | |
| SCHEMBL5670108 | 1.00 | FAAH (0.47) | FAAHTERTPTPN1PPARGPPARD | |
| SCHEMBL6243225 | 1.00 | FAAH (0.47) | FAAHTERTPTPN1PPARGPPARD | |
| SCHEMBL5670105 | 1.00 | FAAH (0.47) | FAAHTERTPTPN1PPARGPPARD | |
| SCHEMBL1492198 | 1.00 | FAAH (0.47) | FAAHTERTPTPN1PPARGPPARD | |
| SCHEMBL6243221 | 1.00 | FAAH (0.47) | FAAHTERTPTPN1PPARGPPARD | |
| Hydrochloric Acid SCHEMBL3098493 | 0.98 | FAAH (0.46) | FAAHTERTPTPN1PPARGPPARD | |
| Hydrochloric Acid SCHEMBL10782685 | 0.98 | FAAH (0.46) | FAAHTERTPTPN1PPARGPPARD | |
| Chloromethane SCHEMBL5667965 | 0.98 | FAAH (0.46) | FAAHTERTPTPN1PPARGPPARD | |
| Chloromethane SCHEMBL5667967 | 0.98 | FAAH (0.46) | FAAHTERTPTPN1PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1020 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024038471-A1 | ORAL FORMULATIONS OF EDARAVONE AND IMPROVED METHOD OF MANUFACTURING THEREOF | BDR PHARMACEUTICALS INTERNATIONAL PRIVATE LIMITED (IN) | 2024-02-22 | — | — | WO | claimed |
| EP-4308630-A1 | BIOMEDICAL DEVICES | Bausch + Lomb Ireland Limited (IE) | 2024-01-24 | — | — | EP | claimed |
| WO-2022194737-A1 | BIOMEDICAL DEVICES | BAUSCH + LOMB IRELAND LIMITED (IE) | 2022-09-22 | — | — | WO | claimed |
| US-20210060019-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING IBRUTINIB | NATCO PHARMA LIMITED (IN) | 2021-03-04 | — | — | US | claimed |
| WO-2019142207-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING IBRUTINIB | NATCO PHARMA LIMITED (IN) | 2019-07-25 | — | — | WO | claimed |
| US-9937110-B2 | Translucent gel system | RHODIA OPERATIONS (FR) | 2018-04-10 | — | — | US | claimed |
| EP-2991613-B1 | TRANSLUCENT GEL SYSTEM | RHODIA OPERATIONS (FR) | 2017-11-22 | — | — | EP | claimed |
| US-20160271058-A1 | OPHTHALMIC EMULSION COMPOSITION OF CYCLOSPORINE | GAVIS PHARMACEUTICALS (US) | 2016-09-22 | — | — | US | claimed |
| EP-3068524-A1 | METHOD FOR PREPARING AN ETHANOL FUEL COMPOSITION | SEKAB BioFuels & Chemicals AB (SE) | 2016-09-21 | — | — | EP | claimed |
| US-20160067153-A1 | Translucent gel system | RHODIA OPERATIONS (FR) | 2016-03-10 | — | — | US | claimed |
| US-4474670-A | OIL ADDITIVES | MOBIL OIL CORPORATION (US) | 1984-10-02 | — | — | US | claimed |
| EP-0012523-B1 | THERAPEUTIC COMPOSITIONS WITH ENHANCED BIOAVAILABILITY AND PROCESS FOR THEIR PREPARATION | AMERICAN HOME PRODUCTS CORPORATION (US) | 1984-01-18 | — | — | EP | claimed |
| US-4382006-A | LUBRICANT WITH BORATED TERTIARY ETHOXYLATED AMINE | MOBIL OIL CORPORATION (US) | 1983-05-03 | — | — | US | claimed |
| EP-0067539-A2 | Sustained release pharmaceutical composition | JOHN WYETH & BROTHER LIMITED (GB) | 1982-12-22 | — | — | EP | claimed |
| US-4344934-A | Therapeutic compositions with enhanced bioavailability | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-08-17 | — | — | US | claimed |
| US-4219626-A | Accelerators for radical polymerization reactions with initiators free from peroxide groups | BAYER AKTIENGESELLSCHAFT (DE) | 1980-08-26 | — | — | US | claimed |
| US-4210574-A | WITH TALC OR KAOLIN TREATED WITH AMMONIA OR AN AMINE TO PROVIDE ENHANCED TENSILE STRENGTH | ETHYL CORPORATION (US) | 1980-07-01 | — | — | US | claimed |
| EP-0012523-A1 | Therapeutic compositions with enhanced bioavailability and process for their preparation | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-06-25 | — | — | EP | claimed |
| US-4150054-A | CONTACTING WITH ALCOHOL IN PRESENCE OF PHOSPHORIC ACID AND SALTS OF THE ALIPHATIC AMINO COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 1979-04-17 | — | — | US | claimed |
| US-4014841-A | Aerosol latex paint containing cationic surfactants | ALLIED CHEMICAL CORPORATION (US) | 1977-03-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271058-A1 | OPHTHALMIC EMULSION COMPOSITION OF CYCLOSPORINE | IL5, IL17A, TNF | FAAH 885/4885TERT 1736/4885PTPN1 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.